< Back to previous page
Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization
Journal Contribution - Journal Article
Therapeutic drug monitoring of adalimumab (ADM) has been introduced recently. When no detectable ADM serum concentrations can be found, the formation of antidrug antibodies (ADA) should be investigated. A variety of assays to measure the occurrence of ADA have been developed. Results are expressed as arbitrary units or as a titration value. The aim was to develop a monoclonal antibody (MA) that could serve as a universal calibrator to quantify the amount of ADA in ADM-treated patients.
Journal: Therapeutic Drug Monitoring
Pages: 669 - 73